7 "Bladder Cancer" clinical trials found.
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for ...
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study which will be conducted in 2 parts: a dose-escalation part and a dose expansion part. Patients ...
A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION
If you have had a cystectomy for muscle invasive bladder cancer after neoadjuvant chemotherapy or cannot receive adjuvant chemotherapy, you may qualify to participate ...
A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
The main goal of this phase Ib/2 study is to evaluate safety, preliminary antitumor activity of the investigational drug, Avelumab, a PD-L1 monoclonal antibody, ...
An open-label dose-finding and proof of concept study for Probody Therapeutics (Probody Tx) in subjects with metastatic or locally advanced unrespectable solid tumors and/or lymphomas
An open-label, dose-finding and proof of concept study for Probody Therapeutics (Probody Tx) in subjects with metastatic or locally advanced unrespectable solid tumors and/or lymphomas
A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder
The goal of this phase II trial is to assess the efficacy of pembrolizumab added to concurrent radiation and gemcitabine as bladder-preserving treatment for ...
An Open-Label Randomised Multi-Drug Biomarker-Directed Multi-Centre Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)
If you have been diagnosed with urothelial cancer, which has progressed after prior treatment, you may qualify to participate in a study. The main ...